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Las insulinas análogas basales son opciones eficaces en el tratamiento de pacientes 
con DM2. No obstante, el costo del tratamiento, dado su impacto presupuestal desde 
la perspectiva del pagador, puede afectar la elección del medicamento. ObjectivOs: 
Determinar los costos asociados para alcanzar metas glucémicas con el uso de insu-
linas análogas basales, insulina glargina (IG) vs insulina detemir (ID), a través de 
un modelo de minimización de costos. MetOdOlOgíAs: Búsqueda sistemática de 
literatura en PUBMED de estudios clínicos comparativos entre IG y ID para pacientes 
DM2 insulino-requirentes para extraer datos de uso, efectividad y frecuencia de 
eventos adversos. La meta de control glucémico definida fue HbA1c7%. Los costos 
de insulinas fueron tomados del Sistema Integrado de Precios de Medicamentos 
2011 del Ministerio de Salud y precios de IMS Consulting Group promedio móvil 
anual para noviembre de 2011. Los análisis de sensibilidad se realizaron con simu-
laciones de Monte Carlo en dosis y precios de las insulinas. ResultAdOs: Cinco 
publicaciones cumplieron con criterios de inclusión. La diferencia promedio entre 
dosis de IG e ID fue 15,99U (SD10,04U), a favor de IG. El porcentaje promedio de 
pacientes que requirieron dos dosis con ID fue de 56,2% (SD35,7%). No hubo difer-
encias significativas en eventos hipoglicémicos. Para el canal retail, en 4 estudios 
se apreció un mayor costo entre IG vs ID (Rosenstock USD$435, Hollander USD$532, 
Swinnen USD$967 y Currie USD$357 anuales) a favor de IG y solo un estudio mostró 
mayor costo para IG (Raskin USD$69 anuales). Para el canal institucional, en todos 
los estudios, el tratamiento con IG es la modalidad más económica según costos 
anuales. cOnclusiOnes: La diferencia en dosis promedio entre IG e ID genera una 
diferencia significativa en costos anuales a favor de IG. El uso de IG en el manejo del 
paciente DM2-IR es una alternativa costo/efectiva frente a detemir.
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Objectives: Diabetes is a chronic disease, which when not treated appropriately, 
leads to increased risk of developing preventable complications, increasing the cost 
of care. This represents a heavy burden for the public health budget in Argentina. 
The objective was to collect direct medical costs of treating diabetes-related compli-
cations in Argentina. MethOds: Following a literature review no data on the cost of 
diabetes-related complications were found in Argentina. To obtain robust data, we 
approached 3 local key opinion leaders from both social security (SS) and private (P) 
health care sectors with access to local databases; they covered 3 geographic areas 
of Argentina: Buenos Aires city (P) and Buenos Aires and Cordoba provinces (SS). 
Standardized forms were used for data collection and final values represent average 
cost of the SS and P sectors. Direct costs were classified into 6 groups: disease man-
agement, treatment of acute-events, renal-disease, eye-disease, neuropathy/foot 
ulcers and cardiovascular-complications. Values are presented in 2012 US-dollars 
per “event occurring in the first year” and annual follow up costs (exchange rate 
1USD = 4.89ARS). Results: The diabetes-related complications with highest first 
year average costs were renal-complications (renal transplant 37,833USD; perito-
neal-dialysis 24,655USD and haemodialysis 23,748USD), followed by cardiovascular 
related events (myocardial infarction 5,939USD; congestive heart failure 4,884USD; 
peripheral vascular disease 4,200USD and angina 3,799USD). The cost of an ampu-
tation procedure was 2,727USD while those of prosthesis and post-amputation 
follow up were 3,255USD and 1,470USD, respectively. The cost of eye-laser therapy 
was 449USD while a cataract procedure was 1,186USD. High costs were also associ-
ated with treatment of neuropathy (1,141USD), infected foot ulcer (747USD) and 
gangrene (1,684USD). cOnclusiOns: These findings suggest that implementation 
of prevention strategies to reduce the development of diabetes-related complica-
tions may decrease the diabetes burden on the health care budget. Furthermore the 
data presented will provide useful inputs for economic evaluations in Argentina.
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Objectives: To quantify the annual cost of type 2 diabetes mellitus (T2DM) in Mexico 
and explore the relative contributions of different components of cost. MethOds: A 
cost of illness model was developed in Microsoft Excel 2007 to estimate the economic 
burden of T2DM in Mexico from the public health care payer perspective. Cost of rou-
tine management and complications were included in the analysis. Data inputs for 
prevalence of T2DM (weighted to include only patients who are diagnosed and treated) 
and related complications, costs and routine management were sourced from the pub-
lished literature and publicly available databases, where available. Primary research 
approaching local key opinion leaders was performed to fill data gaps. Sensitivity 
analyses were conducted to identify data inputs which were most likely to impact 
overall results when varied. Costs are presented in Mexican pesos 2012. Results: 
The annual cost of T2DM in Mexico is estimated to be $107,343,890,388MXN($8,643,3
48,612USD). This figure represents ~13% of the national health care expenditure. The 
cost of complications were estimated to account for 91% of the total cost of T2DM, 
with cardiovascular and eye complications accounting for 49% and 18% of total costs, 
respectively. Routine management, including drug costs, was estimated to comprise 
control glucémico tratados con diferentes combinaciones de hipoglucemiantes 
orales con metformina. MetOdOlOgíAs: Mediante una revisión de la literatura se 
identificó y evaluó la efectividad de [vildagliptina, sitagliptina, saxagliptina, lina-
gliptina, glimepiride y glibenclamida] asociados a metformina versus monoterapia 
de metformina (Septiembre 2012). Los estudios encontrados se evaluaron en simili-
tud de diseño y características de los pacientes; y a partir de los resultados de éstos 
se reconstruyeron las distribuciones de Hb1Ac al inicio y a 24 semanas. El análisis 
se hizo por diferencia de medias (reducción de HbaA1c) de acuerdo al método de 
Bacher mediante el software Indirect Treatment Comparison. ResultAdOs: Los 
grupos tratado con vildagliptina de 50, 100 mg y glimepiride no eran similares a 
los tratados con las otras combinaciones respecto al nivel de Hb1Ac de inicio (8,4% 
ee 0,08; 8,3% ee 0,07 y 7,7% ee 0,03 respectivamente) limitando su comparabilidad. 
Las comparaciones entre las demás combinaciones de hipoglucemiantes demos-
traron una mayor reducción de la HbA1c frente a la monoterapia con metformina. 
Ninguna de las combinaciones presentó superioridad en el desenlace analizado, 
aunque presentan diferencias en otros aspectos que pudieran modificar el resul-
tado final como adherencia y presentación de hipoglucemia. cOnclusiOnes: Se 
demuestra la mayor efectividad de las combinaciones de hipoglucemiante-met-
formina versus monoterapia de metformina, en pacientes con Diabetes Mellitus 
e inadecuado control glucémico. No existen diferencias de efectividad cuando se 
mide el nivel de cambio de HbA1C a las 24 semanas. Se requieren análisis que 
tengan en cuenta variables a largo plazo como los eventos micro y macro vascu-
lares y otras variables como la tasa de presentación de hipoglucemia que entre 
las tecnologías analizadas.
DiABetes/enDoCrine DisorDers – Cost studies
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ObjectivOs: Determinar el impacto sobre la unidad de pago por capitación 
(UPC) de la utilización de linagliptina adicionada a metformina en pacientes con 
Diabetes Mellitus tipo 2 (DM2), con inadecuado control glucémico, en el sistema de 
salud de Colombia. MetOdOlOgíAs: A partir de un modelo de costo-efectividad 
que muestra el beneficio de uso de linagliptina adicionada a metformina en el 
tratamiento de pacientes con DM2, se realizó un análisis de impacto presupues-
tario para un quinquenio, considerando costos directos en salud asociados a la 
historia natural de la enfermedad, incluyendo eventos macrovasculares y micro-
vasculares, en una cohorte móvil de pacientes. Los costos directos de atención de 
salud se tomaron de Registros Individuales de las Prestaciones de Salud y de ase-
guradores, con un reemplazo del 50% frente a glibenclamida/metformina (incluida 
en el plan de beneficios del sistema de salud). Se hizo un análisis de sensibilidad 
univariado haciendo variar la tasa de reemplazo. ResultAdOs: Dada una tasa 
de prevalencia de 0,04 e incidencia de 0,00879 de DM2 en Colombia, y el supuesto 
de que el 10% de los pacientes requiere la intervención, el costo acumulado a 5 
años, sería de US$ 2.143.046.352 tratados solo con glibenclamida/metformina, 
frente a US$ 2.067.111.599 si se usa linagliptina adicionada a metformina, con una 
participación del 50%. En el primer año, el impacto de la inclusión de linagliptina 
sería del 0,21% sobre la UPC. Del segundo al quinto año, se generarían ahorros 
sobre la UPC de 0,004%, 0,13%, 0,27% y 0,41%, respectivamente. Es decir, al cabo 
de cuatro años ya sería ahorrativo. Remplazos mayores a 60% generarían más 
ahorros al sistema. cOnclusiOnes: La introducción de linagliptina adicionadaa 
metformina, en el plan de beneficios del sistema de salud colombianoserá nota-
blemente menos costosa que la actual utilización de glibenclamida/metformina, 
en un periodo de cinco años.
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Objectives: Assess cost burden related to drug usage in a long term treatment 
(5 years) in patients with Secondary hyperparathyroidism (SHPT), considering 
hospitalization cost, erythropoietin (EPO) consumption and other direct health 
care costs from an institutional perspective. MethOds: A statistical model was 
developed to simulate an average Mexican patient resources usage in 5 years’ 
time-frame treated with two alternatives paricalcitol and calcitriol based on clin-
ical data in published literature. Resources usage considered: SHPT treatment 
drugs, EPO, hospitalization costs and medical supplies. Unit costs were collected 
from Mexican Government Databases: Instituto Mexicano del Seguro Social (IMSS) 
official database, Official Journal of the Federation (DOF) and Banco de Mexico. 
Univariable sensibility analysis was executed. Results: SHPT medication treat-
ment cost were US$21.92 with calcitriol and US$10,658.00 with paricalcitol during 
five years, while total costs for paricalcitol patients was US$5,304.20(-8.5%) lower 
compared to calcitriol in this time-frame. Most savings occur in hospitalization 
costs where calcitriol patients require in average US$35,633.36 while paricalcitol 
patients required just US$24,532.88. Erythropoietin consumption costs during 5 
years was also lower by US$4,910.88 in paricalcitol patients compared to calcitriol 
(p< 0.05). During the first two years total costs for the patients treated with pari-
calcitol was slightly higher than those treated with calcitriol, US$441.79(+1.7%), 
due to the initial paricalcitol dosage which is reasonably higher than maintenance 
dosage. cOnclusiOns: Based on this cost comparison model, from institutional 
perspective, paricalcitol treatment is less costly when the patient is treated with 
a middle-term (more than 2 years) or long-term (5 years) perspective at IMSS in 
Mexico.
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costs and Life-years gained (LYG) offset based on incremental survival rate of compared 
therapies. Probabilistic Multivariable sensibility analysis was completed with 5,000 
simulated patients. Results: Survival rate and confidence interval obtained from 
model was 0.63 (0.60, 0.66) for paricalcitol and 0.46 (0.44, 0.48) for PTX. Average survival 
of both therapies resulted in an incremental 0.61 LYG for paricalcitol patients (+18%). 
Average five years treatment cost for Paricalcitol patients was $10,024.25, while PTX 
was US$5,369.74(-46%) resulting in an ICER of US$7,619.94 per LYG, which is 28.2% 
below Mexican Gross Domestic Product (GDP) per capita. Probabilistic analysis shown: 
90.1% of patient treated had a cost-effective outcome and 7.2% of cases had a domi-
nant outcome. cOnclusiOns: According to results obtained and using a threshold 
of US$29,306.29 (3 x GDP per capita), Paricalcitol is a highly cost-effective treatment 
option compared to PTX when treating patients with SHPT at IMSS.
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Objectives: Type 2 Diabetes is a major public health care problem in Mexico. Some 
patients may require more than one oral antidiabetic treatment to achieve glycemic 
control. Vildagliptin, a DPPIV inhibitor is an option in combination with the stand-
ard treatment of metformin. The objective was to assess the cost-effectiveness of 
Vildagliptin/Metformin FDC versus other oral treatments available in the public 
market. MethOds: Cost-effectiveness analysis of the oral antidiabetic treatments 
available in the public market in Mexico was conducted. The comparisons included 
the following options: Vildagliptin/Metformin FDC, glibenclamide, and thiazolidin-
ediones (Rosiglitazone and pioglitazone). Cost effectiveness analysis versus other 
oral antidiabetics incorporated the incidence and costs of adverse events according 
to Ferrannini 2009 and Gonzalez-Ortíz 2009 for glibenclamide and Motola 2012 for 
thiazolidinediones. Drug costs were elicited from public tenders and health care 
services from unitary costs of the IMSS. The perspective is the public health provider 
and the time horizon is one year. Results: The use of Vildagliptin/Metformin FDC 
(50/500 or 850 mg) BID compared to glibenclamide, is a dominant strategy if the cost 
per hypoglycemia exceeds US$714.03. Vildagliptin/Metformin FDC is dominant ver-
sus pioglitazone,if the cost of fractures incurred by pioglitazone exceeds US$56.56. 
Drug acquisition costs of Vildagliptin/Metformin FDC are 150% cheaper per patient 
treated vs rosiglitazone; additionally rosiglitazone is associated with myocardial 
infarction events. cOnclusiOns: Vildagliptin/Metformin FDC is an opportunity 
for resource optimization in the public sector. This cost effectiveness analysis is 
not considering other potential adherence benefits which are related with having 
two treatments in one pill.
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Objectives: To perform a probabilistic sensitivity analysis to analyze previously 
reported results about the cost-effectiveness of oral hypoglycemic agents (OHA’s) 
in the initial oral drug treatment of patients diagnosed with type 2 diabetes mel-
litus in public primary attention in Mexico. MethOds: A probabilistic sensitivity 
analysis was made in order to analyze results previously reported in which a deter-
ministic sensitivity analysis was performed to study the cost-effectiveness of three 
OHA’s: metformin, glibenclamide and acarbose. We used TreeAge-Pro® software for 
programming and simulating a Markov model of two health states (HbA1C≤ 7% or 
HbA1C> 7%) and twelve cycles of 1 month for a time horizon of 1 year. The parameters 
of monthly success probability as beta distributions and monthly costs as lognormal 
distributions of therapeutic alternatives were computed through a parametrization 
of data. Monte Carlo’s simulations were computed for cohorts of 10,000 patients 
for each treatment option. Results: The results of the Monte Carlo’s simulations 
showed very close iterations clouds for metformin and glibenclamide showing evi-
dent dominance of both over acarbose. In the acceptability curve generated, for a 
willingness to pay (WTP) = 0 the probabilities to be cost-effective were 49.46 %, 43.04 
% and 7.50 % for glibenclamide, metformine and acarbose, respectively, whereas for 
a WTP = 1 mexican GDP per capita (US $ 7876.00 in 2009) were 66.26 %, 26.98 % and 
6.76%. The glibenclamide versus metformin incremental cost-effectiveness analysis 
showed similar results as mentioned before, showing 59.72% of iterations below the 
WTP = 1 mexican GDP per capita line. cOnclusiOns: The probabilistic sensitivity 
analysis showed which the initial drug therapy with glibenclamide or metformin 
have advantage over acarbose. There is not sufficient evidence to say glibenclamide 
has advantage over metformin for WTP near to cero, as in low to middle income 
countries where containment of expenditures is important.
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Objectives: Canagliflozin (CANA) is a novel inhibitor of the sodium glucose co-
transporter 2 in development for treating patients with type 2 diabetes mellitus 
(T2DM). In a previously reported randomized, double-blind, 4 arm parallel group 
(placebo, CANA 100mg, CANA 300mg and sitagliptin 100mg [SITA]) study of 1284 
subjects inadequately controlled on MET monotherapy, CANA 100mg and 300mg 
significantly decreased HbA1c versus placebo after 26 weeks of therapy by 0.62% and 
0.77%, respectively; SITA decreased HbA1cversus placebo by 0.65%. In this trial, both 
9% of total cost of T2DM. The cost estimate was most sensitive to incidence and event 
cost of peripheral vascular disease, stroke and severe vision loss. cOnclusiOns: 
Based on the present analysis, T2DM places a significant financial burden on the 
health care system in Mexico, with cost of treating related complications being the 
main cost driver. Given the model focuses on diagnosed and treated T2DM patients, 
it is likely this cost is even higher when undiagnosed and untreated patients are 
considered. Delaying the onset of complications could result in a reduction in costs, 
as well as benefits for the patient and health care system.
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Objectives: This study aimed to quantify the annual financial cost of type 2 diabe-
tes (T2DM) in Brazil and explore the relative contribution of different components 
of cost. MethOds: A cost of illness model was developed in Microsoft Excel 2007 
to estimate the financial cost of T2DM in Brazil from the public health care payer 
perspective. Cost of routine management and complications were included in the 
analysis. Data inputs for prevalence of T2DM (weighted to include only patients who 
are diagnosed and treated) and related complications, costs and routine management 
were sourced from the published literature and publicly available databases, where 
available. Key opinion leader input was sought to fill data gaps. Sensitivity analyses 
were conducted to identify parameters which were most likely to impact overall 
results when varied. Costs are presented in Brazilian Reals 2012. Results: The annual 
cost of T2DM in Brazil is estimated to be 11,275,921,167 BRL ($5,471,123,022USD) which 
represents 5.3% of national health care expenditure. Costs of complications were 
estimated to account for 56% of the total cost of T2DM. Cardiovascular complica-
tions accounted for 32% of total T2DM cost. Diabetes drug costs were estimated to 
account for 31% of total T2DM health care spending. The overall cost estimate was 
most sensitive to the laser eye surgery, hemodialysis and cardiovascular complica-
tions and the frequency and cost of routine physician consultations. cOnclusiOns: 
The findings indicate that there is a high economic burden of T2DM for the Brazilian 
health care system. Cost of treating related complications was the main driver. An 
even higher burden of the disease is expected if undiagnosed and patients currently 
not being treated start receiving public medical attention. The burden of the disease 
could considerably be reduced if T2DM related complications were avoided, which 
not only benefits the health care system but the patients as well.
PDB8
trenDs in heAlth CAre resourCes utilizAtion, Cost AnD meDiCAtion 
seleCtion in the treAtment oF DiABetes
Lachaine J., Beauchemin C.
University of Montreal, Montreal, QC, Canada
Objectives: Diabetes is one of the most common chronic diseases in Canada. It 
affects about 6.8% of the Canadian population. Treating and managing the disease 
and its complications is associated with a significant economic burden. The objec-
tive of this study was to analyse trends in terms resource utilization, cost and treat-
ment patterns in the management of diabetes. MethOds: Patients covered by the 
Quebec provincial drug reimbursement program (RAMQ) who had a diagnosis of 
diabetes, in 2005 and were covered continuously by the public drug program for the 
period from January 2006 to December 2010 were selected. Health care resources in 
terms of diabetes medications and physician visits, hospitalization, intensive care 
unit stay, hospital outpatient clinic visits, and emergency room visits associated 
with a diagnosis of diabetes were estimated over a 5-year period, from January 2006 
to December 2010. Trends in the proportion of diabetes medications used each year 
over the 5-year study period were also estimated. Results: A total of 46,194 diabetic 
patients were included in the study. The mean age of the study population was 65.4 
years (SD= 12.3) and proportion of male/female was 47% and 53% respectively. Over 
the study period, annual cost of diabetes medications varied from $320 (SD= 464) in 
2006 to $372 (SD= 546) in 2010 (+16%) while total cost of treatment associated with 
diabetes varied from $627 (SD= 1456) to $715 (SD= 1632) (+14%) during that period. 
Metformine remains the most widely used medication throughout the study period 
with 64.3% of users in 2006 and 65.6% in 2010. Proportion of insulin users increased 
from 15.2% to 22.7% while gliclazide users increased from 4.4% to 11.2% during the 
study period. cOnclusiOns: Over the five-year study period cost of diabetes treat-
ment has increased at a rate similar to inflation, while trends of increased adoption 
of insulin and newer medications is observed.
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Objectives: Secondary hyperparathyroidism (SHPT) affects one of every two 
Mexicans with chronic kidney disease (CKD) at stage five. The objective of this research 
was to assess cost effectiveness (CE) of Paricalcitol intravenous administration (IV) ver-
sus parathyroidectomy (PTX) from Mexican payer perspective. MethOds: A decision 
tree model was designed to simulate patient resources usage and survival rate in 5 
years time-frame treated with paricalcitol IV and parathyroidectomy based on clinical 
data in recent published literature. Time-frame begins when a patient is refractory 
to Calcitriol therapy and physician decides to treat with Paricalcitol or program PTX. 
Resources usage considered were just directly related to SHPT treatment: drug cost, 
surgery and hospitalization costs and medical supplies linked. Unit costs were col-
lected from Mexican Government Databases: IMSS official database, Diagnosis Related 
Groups from IMSS, Official Journal of the Federation. (Cost considered 5% annual dis-
count rate).Incremental Cost-Effectiveness Ratio (ICER) was calculated with treatment 
